Top in rheumatology: Hip osteoarthritis burden, breakthrough SARS-CoV-2 infections

A recent analysis showed the global burden of hip osteoarthritis rose between 1990 and 2019, with incidence and disability-adjusted life years increasing in most countries. A report on the data was the top story in rheumatology last week.

Another top story was about the risk for SARS-CoV-2 breakthrough infections, which appeared to be higher among people with immune dysfunction, particularly those with rheumatoid arthritis, HIV and solid organ transplant, according to researchers.

Read these and more top stories in rheumatology below:

Hip osteoarthritis burden increasing 'in almost all countries'

The burden of hip osteoarthritis has increased globally in the past 30 years, with incidence and disability-adjusted life years rising “in nearly all countries,” according to data published in Arthritis Research & Therapy. Read more.

Immune dysfunction linked to 'substantial risk' for breakthrough COVID-19 infection

Although vaccines reduce the overall risk for COVID-19 regardless of immune status, patients with immune dysfunction are at a “substantial risk” for breakthrough infection versus those without, according to data. Read more.

Biosimilar, originator DMARDs exhibit no differences in treatment retention

There are no clinically relevant differences in treatment retention among patients receiving biosimilar or originator biologic disease-modifying antirheumatic drugs as first exposure to that drug, data published in Rheumatology show. Read more.

More than 60% of patients with RA, PsA report side effects in days after methotrexate dose

Approximately 61% of patients with rheumatoid arthritis or psoriatic arthritis who use methotrexate report side effects following weekly dosing, including fatigue and nausea, according to data published in Rheumatology and Therapy. Read more.

IgG4-related disease linked to increased risk for lymphoma, pancreatic cancer

Patients with IgG4-related disease are at a higher risk for cancer — particularly pancreatic and lymphoma — compared with the general population, according to a meta-analysis published in Arthritis Research & Therapy. Read more.